Hygieia Biotech showcases Ca-AKG and nutraceutical ingredients at CPHI Korea

Hygieia Biotech wrapped up its CPHI Korea 2026 showing in Seoul after highlighting Ca-AKG, NMN and other biosynthetic nutraceutical ingredients for healthy aging, cellular health and women’s health. The company is now lining up a follow-on appearance at Vitafoods Asia 2026 in Bangkok.

Why it matters: - Hygieia Biotech is positioning itself as a supplier for supplement brands and manufacturers that want more than bulk ingredients. - The company is emphasizing technical documentation, formulation support and scalable supply, which are increasingly important in B2B nutraceutical sourcing. - The portfolio spans healthy aging, cellular health, women’s health, energy support, antioxidant protection and brain health.

What happened: - Hygieia Biotech concluded its participation in CPHI Korea 2026 at the COEX Convention & Exhibition Center in Seoul. - The company exhibited at Booth F28 and showed a focused portfolio of nutraceutical and functional ingredients. - Visitors included supplement brands, ingredient distributors, formulators, manufacturers and other industry professionals from Korea and international markets. - Hygieia also said it will exhibit at Vitafoods Asia 2026 from September 2-4, 2026, at the Queen Sirikit National Convention Center in Bangkok. - The company plans to show at Booth H7-S41 at Vitafoods Asia 2026.

The details: - Ca-AKG, including Hygieia’s EnerLive® Ca-AKG, was a major focus at the Seoul show. - Ca-AKG is associated with cellular metabolism and healthy aging research. - Discussions covered ingredient specifications, quality requirements, bulk sourcing, formulation considerations, technical documentation, product-development opportunities and long-term supply planning. - Hygieia said EnerLive® Ca-AKG is supported by technical and scientific documentation for B2B ingredient evaluation. - The broader portfolio included S-Allyl-L-Cysteine, Urolithin A and Spermidine for cellular health and antioxidant support. - The portfolio also included D-Chiro-Inositol, L-5-MTHF-Ca and S-Equol for women’s health. - NMN and Ca-AKG were highlighted for NAD+ and energy-related applications. - Hygieia’s Zymevolver® platform combines strain engineering, enzyme optimization and biosynthetic process development. - The company says biosynthetic production can offer advantages in process control, molecular specificity and manufacturing consistency, depending on the ingredient and pathway. - Hygieia supports projects with product specifications, Certificates of Analysis, Safety Data Sheets, quality and testing documentation, stability information where applicable, and regulatory and compliance documents. - Hygieia also offers bulk ingredient supply, technical and quality support, formulation support, and OEM and ODM manufacturing. - At Vitafoods Asia 2026, Hygieia plans to highlight Ca-AKG, NMN and D-Chiro-Inositol. - The Bangkok event will focus on sourcing, healthy aging, cellular health, women’s health, NAD+ and energy ingredients, bulk supply, formulation development, and OEM and private-label opportunities.

Between the lines: - Hygieia is using trade shows to sell a full-service ingredient platform, not just individual raw materials. - The message reflects a wider industry shift: buyers want sourcing support, documentation and product-development help before they place commercial orders. - The company’s biosynthetic manufacturing pitch is aimed at customers that care about consistency and supply reliability as much as ingredient novelty.

What's next: - Hygieia will take the same ingredient and development pitch to Vitafoods Asia 2026 in Bangkok. - The company says its technical and sales teams will meet with industry professionals to discuss samples, documentation, formulation requirements and commercial supply opportunities. - Hygieia plans to keep expanding its biosynthetic ingredient portfolio and B2B support model for global markets.